89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 28,400 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on the later of February 2, 2024 and the employee’s commencement of employment with the Company (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (ETNB)
- Morning Market Surge: Innovation, M&A, and Strategic Expansion Drive Early Action
- Breaking News: MoBot’s Latest Update as of 05/20/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/20/25 02:00 PM
- 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- 89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares